Özet:

Background and Aims:Although many serological markers associated with inflammatory bowel disease have been defined, the evidence that interacts with clinical results is limited. We aimed to evaluate the relevance of anti-pancreatic antibody, p-ANCA and ASCA in the differential diagnosis of inflammatory bowel disease and their correlation with disease activity. Materials and Methods:The presence of antipancreatic antibody, p-ANCA and ASCA was determined in indirect immunofluorescence assay of serum samples from 95 patients with inflammatory bowel disease (63 ulcerative colitis, 29 Crohn's disease, 3 indeterminate colitis) and 65 healthy controls. Results:Anti-pancreatic antibody was present in 6,9% (2/29) in Crohn's disease and 3,2% (2/63) in ulcerative colitis. Anti-pancreatic antibody was not detected in the indeterminate colitis and control groups. No statistical difference was found between ulcerative colitis and Crohn's disease in terms of anti-pancreatic antibody incidence. p-ANCA was detected in 46% (29/63) in ulcerative colitis, 13,8% (4/29) in Crohn's disease, 66,6% (2/3) in indeterminate colitis, and 4,6% (3/65) in the control group. pANCA was statistically higher in ulcerative colitis compared to Crohn's disease. ASCA was present in 34,5% (10/29) in Crohn's disease, 7,9% (5/63) in ulcerative colitis and 3,1% (2/65) in the control group. ASCA was not detected in the patients with indeterminate colitis. ASCA was statistically higher in Crohn's disease compared to ulcerative colitis. It was found that anti-pancreatic antibody, p-ANCA and ASCA were not associated with disease activity in inflammatory bowel disease. Conclusions:We may conclude that anti-pancreatic antibody can be associated with inflammatory bowel disease, but it is not sufficient by itself for the differential diagnosis of inflammatory bowel disease. ASCA and p-ANCA may be helpful tools in the differential diagnosis of inflammatory bowel disease, but more studies are warranted for antipancreatic antibody

Anahtar Kelimeler: